Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | GRM1 | Q13255 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.34 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA3 | P07451 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA6 | P23280 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4692150 | 0.89 | GRM1 (0.43) | HSD17B10GRM1MEN1KMT2ATBXAS1 | |
| SCHEMBL7241230 | 0.87 | GRM1 (0.39) | HSD17B10GRM1RPS6KA5CA12CA2 | |
| SCHEMBL4693300 | 0.83 | MAPT (0.41) | HSD17B10GRM1MEN1KMT2ARPS6KA5 | |
| Hydrochloric Acid SCHEMBL7232019 | 0.81 | GRM1 (0.39) | GRM1TSHRSMN1; SMN2 | |
| SCHEMBL4693948 | 0.80 | GRM1 (0.40) | HSD17B10GRM1RPS6KA5 | |
| SCHEMBL4688818 | 0.80 | CNR2 (0.35) | HSD17B10GRM1 | |
| SCHEMBL7241226 | 0.77 | GRM1 (0.47) | HSD17B10GRM1MEN1KMT2ACA12 | |
| SCHEMBL7239242 | 0.77 | SMN1; SMN2 (0.42) | HSD17B10MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4694711 | 0.77 | GRM1 (0.42) | HSD17B10GRM1RPS6KA5PRKACARPS6KB1 | |
| SCHEMBL7238159 | 0.76 | ALOX5AP (0.33) | GRM1HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1486501-B1 | AMINOMETHYL-SUBSTITUTED THIAZOLOBENZIMIDAZOLE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2008-09-10 | — | — | EP | disclosed |
| US-7250429-B2 | Aminomethyl-substituted thiazolobenzimidazole compounds | ASTELLAS PHARMA INC. (JP) | 2007-07-31 | — | — | US | disclosed |
| US-20050148642-A1 | Aminomethyl-substituted thiazolobenzimidazole derivative | ASTELLAS PHARMA INC. (JP) | 2005-07-07 | — | — | US | disclosed |
| EP-1486501-A1 | AMINOMETHYL-SUBSTITUTED THIAZOLOBENZIMIDAZOLE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-12-15 | — | — | EP | disclosed |
| US-6642264-B1 | Thiazolo(3,2-a)benzoimidazole derivatives act specifically on metabotropic glutamate receptors and are used as medicaments. | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2003-11-04 | — | — | US | disclosed |
| EP-1167369-A1 | NOVEL THIAZOLOBENZIMIDAZOLE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2002-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148642-A1 | Aminomethyl-substituted thiazolobenzimidazole derivative | GRM1, GRIN1, GRM3 | HSD17B10 1391/4885GRM1 1/4885MEN1 2545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.